3Brain AG developed and distributes the world’s first commercial CMOS-based high-resolution Microelectrode Array (MEA), a Biosensor integrating thousands of tiny electrical sensors in a small area. This Biosensor allows non-invasive (in vitro) investigations of electrogenic cells, such as neurons, cardiac and muscle cells. The technology can be used to investigate electroactive cells’ fundamental properties, to study and find new treatments to different types of diseases, and to assess compounds/chemical toxicity.
Founded in 2011, 3Brain AG is a privately held company based in Freienbach, Schwyz, Switzerland, with a team of 54 employees. The company’s innovative approach to biosensor technology has positioned it as a leader in the field of electrogenic cell research.
3Brain AG’s technology is particularly valuable for pharmaceutical companies, research institutions, and academic labs focused on neuroscience, cardiology, and pharmacology. By providing a non-invasive method to study cellular activity, 3Brain AG’s MEA technology supports the development of new treatments and the understanding of disease mechanisms.
Tip: The CEO isn't always your best path in. Data Surfer finds the champions and influencers who actually drive purchasing decisions.
| Ownership Private Company |
B2B professionals should contact 3Brain AG for access to cutting-edge biosensor technology that can significantly enhance research and development in neuroscience, cardiology, and pharmacology. The company’s innovative solutions offer a competitive edge in drug discovery and disease research.
Sales teams selling research equipment, pharmaceutical companies, and academic institutions should reach out to 3Brain AG. Recruiters seeking roles in neuroscience, biomedical engineering, and pharmaceutical research should also consider this company.
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with 3Brain AG